Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Timothy W. Morris"'
Autor:
David Hasan, Timothy W. Morris, Alberto Varon, Ryan Sabotin, Daizo Ishii, Ashrita Raghuram, Jorge A Roa, Devanshee Patel, Edgar A. Samaniego, Yongjun Lu
Publikováno v:
World Neurosurgery. 147:e538-e551
To correlate the presence of objectively measured wall enhancement on high-resolution vessel wall imaging (HR-VWI) with the clinical predictive scales PHASES, ELAPSS, and UIATS.Patients with unruptured intracranial aneurysm (UIAs) prospectively under
Publikováno v:
Clinical Ophthalmology, Vol 2010, Iss default, Pp 215-225 (2010)
Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Steri
Externí odkaz:
https://doaj.org/article/558707f1c679417aa2490cd37df17be9
Autor:
Mario Zanaty, Jorge A Roa, Anthony Piscopo, Daizo Ishii, Timothy W. Morris, Alberto Varon, Ashrita Raghuram, David Hasan, Ryan Sabotin, Yongjun Lu, Edgar A. Samaniego
Publikováno v:
Cardiology and Cardiovascular Medicine.
Background: Wall enhancement of unruptured intracranial aneurysms (UIAs) on high-resolution vessel wall imaging (HR-VWI) has been applied as a surrogate of inflammation. MR-quantitative susceptibility mapping (QSM) can identify microbleeds (MBs) at t
Autor:
Radhika Tandon, Umang Mathur, Parul Sony, Timothy W. Morris, Timothy L. Comstock, Prashant Garg
Publikováno v:
Asia-Pacific Journal of Ophthalmology. :1-6
PURPOSE To evaluate the efficacy of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% in the treatment of bacterial conjunctivitis in an Indian population. DESIGN Multicenter, randomized, double-masked, activ
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Wolfgang Haas, Christine M Sanfilippo, Christine K Hesje, Timothy W Morris Department of Microbiology and Sterilization Sciences, Bausch + Lomb, Inc, Rochester, NY, USA Introduction: Previous work has shown that besifloxacin, an 8-chloro-fluoroquinol
Autor:
Lynne S. Gearinger, Jesse DeLeon, Kirk Bateman, Bruce E. Silverstein, Timothy L. Comstock, Catherine Allaire, Timothy W. Morris
Publikováno v:
Clinical Drug Investigation. 32:303-317
Background and Objective: Besifloxacin ophthalmic suspension 0.6% given thrice daily for 5 days is safe and effective in the treatment of patients with bacterial conjunctivitis. This study evaluated the safety and efficacy of besifloxacin ophthalmic
Publikováno v:
Current Eye Research. 36:1078-1085
Outbreaks of bacterial conjunctivitis have been linked to nontypeable strains of Streptococcus pneumoniae that lack a capsule, a key virulence factor for invasive infections. In contrast, isolates from sporadic, nonoutbreak cases of conjunctivitis we
Autor:
Wolfgang Haas, Christine M Sanfilippo, Timothy W. Morris, Chris M. Pillar, Christine K. Hesje
Publikováno v:
Journal of Antimicrobial Chemotherapy. 66:840-844
To compare the bactericidal activity of besifloxacin, moxifloxacin and gatifloxacin and determine the contribution of the preservative benzalkonium chloride (BAK) to bactericidal activity.Time-kill experiments were performed against four species (n=1
Publikováno v:
Chemotherapy. 57:363-371
Background: The impact of mutations in DNA gyrase and topoisomerase IV on minimum inhibitory concentrations (MICs) was investigated to better understand why besifloxacin has a higher potency against Staphylococcus aureus when compared to other fluoro
Publikováno v:
Current Eye Research
Purpose: Methicillin-resistant Staphylococcus aureus (MRSA) strains are commonly classified as hospital-acquired (HA) or community-acquired (CA). Typical HA-MRSA isolates are characterized by multidrug resistance and the SCCmec type II cassette, whil